{
  "id": "mhgap#screening_cues_d711b669",
  "title_en": "General — Screening Cues",
  "title_vi": "General — Dấu hiệu sàng lọc",
  "text_en": "5. Monitoring and evaluating the impact of the guideline After the publication of this mhGAP guideline, where possible, including the Atlas: country resources WHO will continue to collect regular feedback from for neurological disorders (23), the Comprehensive implementation activities to evaluate their usefulness mental health action plan 2013–2030 (14), the Mental and impact. WHO will additionally continue to collect health atlas 2020 (24), indicators provided as part of feedback from international experts and health workers implementing WHO’s Intersectoral global action plan who are familiar with using the mhGAP guideline. This on epilepsy and other neurological disorders 2022–2031 information will be used to evaluate the effects of the (3), the Global action plan on the public health response guideline on processes and health outcomes and to to dementia 2017–2025 (15) and the Global alcohol ensure the quality of the guideline and identify areas to action plan 2022–2030 (16). be improved. This will draw on existing WHO resources 113 6. Updating the evidence The guideline will be updated five years after or a change in the published recommendation may publication. The WHO Steering Group will continue be warranted, respectively. Following publication and to follow the research developments in the mhGAP dissemination of the guideline, any concern about module areas, particularly those questions for which no validity of any recommendation would be promptly evidence was found and those that were supported by communicated to the guideline implementers in low-certainty evidence, where new recommendations addition to plans to update the recommendation. 114",
  "gloss_vi": "5. monitoring and evaluating the impact of the guideline after the publication of this mhgap guideline, where possible, including the atlas: country resources who will continue to collect regular feedback from for neurol...",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "screening_cues",
      "psychoeducation"
    ],
    "life_topics": [
      "work"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Screening Cues General — Dấu hiệu sàng lọc 5. Monitoring and evaluating the impact of the guideline After the publication of this mhGAP guideline, where possible, including the Atlas: country resources WHO will continue to collect regular feedback from for neurological disorders (23), the Comprehensive implementation activities to evaluate their usefulness mental health action plan 2013–2030 (14), the Mental and impact. WHO will additionally continue to collect health atlas 2020 (24), indicators provided as part of feedback from international experts and health workers implementing WHO’s Intersectoral global action plan who are familiar with using the mhGAP guideline. This on epilepsy and other neurological disorders 2022–2031 information will be used to evaluate the effects of the (3), the Global action plan on the public health response guideline on processes and health outcomes and to to dementia 2017–2025 (15) and the Global alcohol ensure the quality of the guideline and identify areas to action plan 2022–2030 (16). be improved. This will draw on existing WHO resources 113 6. Updating the evidence The guideline will be updated five years after or a change in the published recommendation may publication. The WHO Steering Group will continue be warranted, respectively. Following publication and to follow the research developments in the mhGAP dissemination of the guideline, any concern about module areas, particularly those questions for which no validity of any recommendation would be promptly evidence was found and those that were supported by communicated to the guideline implementers in low-certainty evidence, where new recommendations addition to plans to update the recommendation. 114 5. monitoring and evaluating the impact of the guideline after the publication of this mhgap guideline, where possible, including the atlas: country resources who will continue to collect regular feedback from for neurol..."
}